Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP): effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma

Journal Article · · Cancer Treat. Rep.; (United States)
OSTI ID:6010191
Twenty-three patients with metastatic non-oat cell bronchogenic carcinoma (MN0BC) were treated with cyclophosphamide, adriamycin, methotrexate,and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 months for responding patients and patients with stable disease. Lung, liver, and cutaneous sites of involvement proved to be highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.
OSTI ID:
6010191
Journal Information:
Cancer Treat. Rep.; (United States), Journal Name: Cancer Treat. Rep.; (United States) Vol. 60:9; ISSN CTRRD
Country of Publication:
United States
Language:
English

Similar Records

Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: a prospective study. [/sup 60/Co]
Journal Article · Tue Jun 01 00:00:00 EDT 1982 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6783081

Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity
Conference · Wed Aug 01 00:00:00 EDT 1979 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5339501

Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study
Journal Article · Wed Jan 31 23:00:00 EST 1990 · Cancer (Philadelphia); (USA) · OSTI ID:7190677